A Phase I Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer

Protocol
09-035
Full Title
A Phase I Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer
Phase
I
Purpose

Image-guided intensity-modulated radiation therapy (IG-IMRT) is a form of radiation therapy to treat prostate cancer. Typically, this treatment requires patients to come in for one-hour radiation therapy sessions five days a week for eight to nine weeks.

The purpose of this study is to evaluate the side effects associated with escalating doses during a shorter course of radiation therapy called ultra-hypofractionated IG-IMRT in men with prostate cancer. This therapy is delivered every other day for a total of five treatments which can be completed within two weeks.

The radiation delivered during ultra-hypofractionated IG-IMRT is a higher, more targeted dose than the conventional approach. By the end of treatment, patients should receive a total radiation dose that is equal to or greater than the standard approach.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have a confirmed diagnosis of low-risk or intermediate-risk prostate cancer and be candidates for radiation therapy.
  • Patients may not have had prior hormonal therapy for prostate cancer.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Michael Zelefsky at 212-639-6802.

Disease(s)
Prostate Cancer
Prostate Cancer: Localized Disease
Related Diseases